Patents & Publications


ID Number
Date Filed
Elements Covered
US Patent 9,897,090
Fusion proteins and immunoconjugates and uses thereof which are specific for glycophorin A
INSERM/ Erganeo
March 4, 2014
Issued in US. Exclusive license for therapeutics
An antibody element for safe targeting to red blood cells
Application WO2022/ 272026A1
Methods and Compositions Relating to Tissue-protective Erythropoietin
June 24, 2022 (Utility)
Terms agreed upon with Harvard
Fusion proteins for treatment of hypoxia


  • Way JC, Burrill DR, Silver PA. Bioinspired Design of Artificial Signaling Systems.  Biochemistry 2022.
  • Lee JM, Redfield K, Way J Silver P. Minimizing side effects, maximizing returns: what makes a smart therapeutic design?  The Biochemist, June 2019 p 28-32.
  • Lee J et al. Rational engineering of an erythropoietin fusion protein to treat hypoxia.  Protein Eng Des Sel. 2021;34:gzab025.
  • Lee J, Vernet A, Redfield K, Lu S, Ghiran IC, Way JC, Silver PA.  2020. Rational Design of a Bifunctional AND-Gate Ligand To Modulate Cell−Cell Interactions.  ACS Synthetic Biology 9:191-197.
  • Burrill DR, Vernet A, Collins, JJ, Silver PA, Way JC. 2016. Targeted erythropoietin selectively stimulates red blood cell expansion in vivo. PNAS. 113(19):5245-50.  
  • Robinson-Mosher A, Shinar T, Silver PA, Way JC. 2013. Dynamics simulations for engineering macromolecular interactions. Chaos 23(2): 025110.
  • Taylor ND, Way JC, Silver PA, Cironi P. 2010. Anti-glycophorin single-chain Fv fusion to low-affinity mutant erythropoietin improves red blood cell-lineage specificity. Protein Engineering, Design & Selection Vol (23) no. (4) 251-60.
  • Cironi P, Swinburne IA, Silver PA. 2008. Enhancement of Cell Type Specificity by Quantitative Modulation of a Chimeric Ligand. J Biol Chem 283(13):8469-76.
  • Way JC, Collins JJ, Jay D Keasling JD, Silver PA. Integrating biological redesign: where synthetic biology came from and where it needs to go. Cell 2014. 157(1):151-61.  doi: 10.1016/j.cell.2014.02.039.
  • Habib I et al. V(H)H (nanobody) directed against human glycophorin A: a tool for autologous red cell agglutination assays. Anal Biochem. 2013;438(1):82-9. doi: 10.1016/j.ab.2013.03.020.
  • Kontos S et al. Engineering antigens for in situ erythrocyte binding induces T-cell deletion. Proc Natl Acad Sci. 2013;110(1):E60-8.